Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

BACKGROUND: Adalimumab (ADA) (Humira(®), AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis. OBJECTIVES: To evaluate the long‐term efficacy and safety of ADA in children with severe plaque psoriasis. METHODS: Results are present...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, D., Papp, K., Marcoux, D., Weibel, L., Pinter, A., Ghislain, P.‐D., Landells, I., Hoeger, P.H., Unnebrink, K., Seyger, M.M.B., Williams, D.A., Rubant, S., Philipp, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916374/
https://www.ncbi.nlm.nih.gov/pubmed/31017657
http://dx.doi.org/10.1111/bjd.18029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916374/
https://www.ncbi.nlm.nih.gov/pubmed/31017657
http://dx.doi.org/10.1111/bjd.18029

Ejemplares similares